Business Overview: Liquidia Corporation (NASDAQ: LQDA)

---

Executive Summary

Liquidia Corporation is a commercial-stage biopharmaceutical company focused on therapies for rare cardiopulmonary and pulmonary diseases, principally pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Its lead commercial product, YUTREPIA (treprostinil) inhalation powder, received FDA approval in May 2025 after a long and litigious regulatory path, and the company also commercializes an injectable treprostinil product under a profit-share arrangement with Sandoz.

Liquidia's business model centers on its proprietary PRINT (Precision Particle Fabrication) drug-delivery technology, which allows it to manufacture dry-powder inhaled formulations with precisely engineered particle characteristics — the technical basis for YUTREPIA's differentiated delivery profile versus existing inhaled and infused treprostinil therapies. The company has been locked in extended patent-infringement and regulatory litigation with United Therapeutics (maker of the competing Tyvaso product line), which has materially shaped Liquidia's commercial launch timeline and remains an ongoing strategic risk and cost.

---

1. Core Business Model & How They Work

[ PRINT Particle-Engineering Platform ] ➡️ [ Dry-Powder Inhaled Treprostinil (YUTREPIA) ] ➡️ [ FDA Approval (May 2025) ] ➡️ [ Commercial Launch to PAH/PH-ILD Patients ] ➡️ [ Pipeline Expansion (L606) ]

Key Operational Drivers

1. Proprietary PRINT drug-delivery platform: Liquidia's particle-engineering technology enables precise, reproducible dry-powder formulations, forming the technical foundation of its competitive differentiation in inhaled prostacyclin therapy.
2. YUTREPIA commercial launch: following FDA approval in May 2025, YUTREPIA generated $148.3 million in 2025 sales (up 74% year-over-year), representing the company's primary near-term growth driver as it ramps commercial uptake among PAH and PH-ILD patients.
3. Treprostinil Injection profit-share with Sandoz: Liquidia also earns profit-share economics on a generic injectable treprostinil product commercialized through Sandoz, providing a complementary, lower-risk revenue stream alongside the YUTREPIA launch.
4. Active patent litigation with United Therapeutics: the company has been engaged in extended litigation with United Therapeutics (maker of Tyvaso/Tyvaso DPI) over patents and regulatory exclusivity, which has significantly shaped — and delayed — Liquidia's path to market and remains an ongoing legal and competitive overhang.
5. Pipeline expansion (L606): Liquidia is developing L606, a liposomal treprostinil formulation, as a potential next-generation product extending the company's prostacyclin-therapy franchise beyond YUTREPIA.

---

2. Product Portfolio

---

3. Competitive Landscape

Liquidia's primary competitor is United Therapeutics, which markets the dominant inhaled and infused treprostinil franchise (Tyvaso, Tyvaso DPI, Remodulin, Orenitram) for PAH and PH-ILD and has aggressively litigated to protect that franchise against YUTREPIA's entry. Other competitors in the broader PAH treatment landscape include companies offering alternative prostacyclin-pathway and endothelin-receptor therapies.

Liquidia's competitive position rests on YUTREPIA's differentiated PRINT-based delivery characteristics (potentially offering dosing or tolerability advantages) and on having successfully navigated FDA approval despite United Therapeutics' legal challenges — but United Therapeutics remains a far larger, more entrenched incumbent with an established prescriber base and greater commercial resources, and ongoing litigation could still affect Liquidia's commercial trajectory.

---

4. Strategic Strengths & Risks

Strengths

• Differentiated delivery technology: the PRINT platform underlies a genuinely distinct formulation approach versus incumbent treprostinil products, supporting FDA approval and a defensible intellectual-property position.
• Strong early commercial ramp: 74% year-over-year sales growth for YUTREPIA in its first full year signals real clinical and market uptake.
• Diversified near-term revenue: the Sandoz injectable profit-share provides cash flow alongside the earlier-stage YUTREPIA launch, reducing total dependence on one product's ramp.

Risks

• Litigation overhang: the protracted patent and regulatory dispute with United Therapeutics has already shaped Liquidia's launch timeline and remains a live risk to commercial exclusivity and cost structure.
• Incumbent competitive resources: United Therapeutics is substantially larger, with an entrenched prescriber base and significantly greater commercial and R&D resources.
• Narrow current product base: commercial revenue is concentrated in YUTREPIA and the Sandoz-partnered injectable; pipeline depth (L606) is still early-stage and unproven.
• Rare-disease market size constraints: PAH and PH-ILD are rare-disease indications, meaning the total addressable patient population — and therefore peak revenue potential — is inherently limited compared to larger therapeutic categories.

---

5. Financial Overview

---

Summary Conclusion

Liquidia has successfully brought a differentiated, PRINT-platform-based inhaled treprostinil therapy to market after a lengthy and contentious legal battle with the dominant incumbent, United Therapeutics, and early commercial results — 74% sales growth in the first full year — suggest real clinical demand for YUTREPIA. The company's moat rests on genuine drug-delivery technology and hard-won regulatory approval rather than scale or network effects, and its near-term trajectory depends heavily on continuing to convert that technological edge into market share within a necessarily limited rare-disease patient population, while managing the ongoing litigation risk posed by a much larger and more entrenched competitor.